LEUVEN, Belgium, May 17th, 2017 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce a […]

(15th February 2015) GALVmed recently held a workshop Nairobi (19-20 January 2017) to discuss ongoing research to improve the East Coast Fever (ECF) vaccine. The vaccine, commonly known as Infection […]

As part of GALVmed’s regulatory harmonisation efforts, a new document was developed to provide a summarised overview of the country requirements and procedures needed to register veterinary products in 30 […]

GALVmed and AgResults are delighted to announce the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine […]

World Animal Vaccination Day promotes the importance of vaccination in all animals. More than 100 animal diseases can be prevented through vaccination, helping to protect many species including dogs, cats, […]

A recent Guardian article has showcased the research, technical innovation and knowledge-sharing partnership between the UK Government and the Bill & Melinda Gates Foundation that is aimed at transforming the […]

GALVmed is collaborating with commercial animal health company, Hester Biosciences Limited and the Jharkhand State Livelihood Promotion Society (JSLPS) to extend poultry and small ruminant vaccination and health care services […]

A new East Coast Fever vaccine diluent improvement project will be undertaken by GALVmed in partnership with the Malawi-based Centre for Ticks and Tick-borne Diseases (CTTBD) and the British-based biotechnology […]

GALVmed collaborated with PATH, a Seattle-based charity working on health care innovations in developing countries, to develop a live LaSota strain Newcastle Disease vaccine that can be freeze dried as […]